This is default featured slide 1 title

Go to Blogger edit html and find these sentences.Now replace these sentences with your own descriptions.This theme is Bloggerized by Lasantha Bandara - Premiumbloggertemplates.com.

This is default featured slide 2 title

Go to Blogger edit html and find these sentences.Now replace these sentences with your own descriptions.This theme is Bloggerized by Lasantha Bandara - Premiumbloggertemplates.com.

This is default featured slide 3 title

Go to Blogger edit html and find these sentences.Now replace these sentences with your own descriptions.This theme is Bloggerized by Lasantha Bandara - Premiumbloggertemplates.com.

This is default featured slide 4 title

Go to Blogger edit html and find these sentences.Now replace these sentences with your own descriptions.This theme is Bloggerized by Lasantha Bandara - Premiumbloggertemplates.com.

This is default featured slide 5 title

Go to Blogger edit html and find these sentences.Now replace these sentences with your own descriptions.This theme is Bloggerized by Lasantha Bandara - Premiumbloggertemplates.com.

Decoding vitamin deficiency and hair fall: Signs, tests and next steps

If you're dealing with hair loss, it might be linked to overlooked nutritional deficiencies. Key vitamins and minerals, like vitamin D, iron, and B12, are vital for optimal hair health. Symptoms such as tiredness, dry hair, or breakage can signal these deficiencies. To diagnose accurately, a blood test is crucial, and seeking professional guidance can help tailor a treatment plan to prevent further hair loss.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/ErtYhNk
via IFTTT

Biocon gets USFDA nod for breast cancer biosimilar Pebrilzo

Biocon Ltd has announced receiving US FDA approval for their biosimilar Pebrilzo, which treats HER2-positive breast cancer. This milestone adds to Biocon's portfolio, increasing their number of oncology biosimilars approved in the United States to five. The company has also secured a global settlement with Genentech for Pebrilzo's earliest licensed launch date in 2028.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/t5fuliF
via IFTTT

Glenmark launches generic of Inlyta tablets for kidney cancer treatment in US

Glenmark Pharmaceuticals Inc has announced the launch of Axitinib Tablets in the United States in two strengths. These tablets are a generic version of Pfizer's Inlyta, used for advanced renal cell carcinoma treatment. The introduction of this product reflects Glenmark's ongoing commitment to providing affordable medicines to patients. Annual sales of Inlyta tablets reached approximately USD 538.4 million in the US during the last year.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/kl7eciL
via IFTTT

Dinaz Vervatwala x The Economic Times

Dinaz Vervatwala established Dinaz's Fitness, a unique women's fitness studio in Hyderabad, back in 1993. Transitioning from a career as a chartered accountant, she emerged as a prominent fitness trainer and wellness coach. Dinaz advocates for a holistic view of wellness, blending mental health and sustainable practices, drawing on her personal journey after overcoming a traumatic accident that instilled in her the values of resilience and consistency.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/l4CVDmo
via IFTTT

Zydus Lifesciences completes 50:50 JV transaction with Sunshine Healthcare Lanka

In a significant strategic move, Zydus Lifesciences Ltd has secured a 50 percent interest in Zydus Sunshine Lifesciences Pvt Ltd, forging a joint venture with Sunshine Healthcare Lanka Limited. This partnership was concluded on November 11, 2026, following a timeline extension that pushed the original closing date from June 26, 2026, to December 2026.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/T4xhX38
via IFTTT

Lupin partner Sandoz launches RanluspecTM across Europe for retinal disease treatment

Lupin Ltd has partnered with Sandoz to launch RanluspecTM, a biosimilar for Ranibizumab, across Europe. This launch will help to improve access to treatments for retinal and choroidal vascular diseases. The European Commission previously approved RanluspecTM in vial and syringe-filled presentations for medical use. The biosimilar targets conditions such as wet age-related macular degeneration and diabetic macular edema.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/fpjaMgs
via IFTTT

Beyond Business: The Leadership Philosophy of T. Kishan Singh

T. Kishan Singh highlights the influence of his father's dedication on his professional journey in the paper industry. He stresses the role of sustainable practices and customer relationships for long-term business success. Health and fitness are prioritized as essential elements for effective leadership and overall well-being. Singh shares that consistency and resilience are vital in navigating challenges, both personally and professionally.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/kLsVhBG
via IFTTT

Deepinder Goyal's $900 Temple wearable faces scrutiny over brain blood-flow claims

Temple, a new wearable device, claims to track blood flow to the brain and other health metrics. Indian doctors express concerns over the validity of these claims, asking for regulatory scrutiny. Some sportspersons promote the device, while critics label it a gimmick without formal medical approvals. Developer Deepinder Goyal states the device is a wellness tracker, not a medical one.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/DI9zTA2
via IFTTT

Aurobindo Pharma arm gets 'Voluntary Action Indicated' classification for Telengana facility from USFDA

Following an inspection from September 7 to September 15, 2026, the US FDA granted Apitoria Pharma, a subsidiary of Aurobindo Pharma, a Voluntary Action Indicated classification. This classification indicates that although objectionable conditions were found in the Telangana manufacturing facility, the absence of immediate regulatory action allows the company to address the issues through voluntary corrective measures.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/IXe8H4Z
via IFTTT

Provisional registration framework proposed for allied healthcare professionals

The National Commission for Allied and Healthcare Professions has proposed a provisional registration framework for eligible professionals, with provisions for bridge courses, supervised clinical training and competency assessments before regular registration. The draft regulations also propose an online registration system and invite public and stakeholder feedback until December 4.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/L2Z4vKU
via IFTTT

CCI clears Advent International's Rs 3,150 crore investment in Yatharth Hospital

Advent International has officially secured the green light from the Competition Commission of India to channel an impressive Rs 3,150 crore into Yatharth Hospitals through its affiliate, Rasmalai Limited. Post-investment, Advent will own a 24.9 percent minority stake in the healthcare entity, which is poised to leverage this financial boost for its expansion efforts and enhancing its healthcare network amidst a backdrop of thriving operational revenues and profit growth.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/ogpiknU
via IFTTT

Pharma industry steps up API investments to cut import dependence, move up value chain

India's pharmaceutical sector is shifting towards high-value medicines and reducing reliance on imports through local manufacturing. Investments in active pharmaceutical ingredients and advanced therapies are on the rise to meet new healthcare demands. Industry leaders highlight the significance of supply-chain resilience and advancements in manufacturing capabilities. Recent data indicates strong domestic market growth and increasing pharmaceutical exports.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/hX7HyBe
via IFTTT

The man behind Lord’s Mark: Dr. Sachidanand Upadhyay features in TIME Magazine for the third consecutive year

Dr. Sachidanand Upadhyay has gained recognition from TIME Magazine for his remarkable contributions to technology and innovation. Lord’s Mark Industries Limited is spearheading key projects in healthcare, defence, and sustainability. With critical product registrations achieved, the company is poised for international growth. Upadhyay envisions transforming India into a prominent technology and manufacturing hub, emphasizing the importance of homegrown innovation in the global marketplace.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/sA9Brbe
via IFTTT

Aayush Wellness reports 10.6% rise in first-half income

Aayush Wellness experienced an increase in consolidated income and profit for the first half of fiscal 2027. The company reported an impressive rise in both consolidated income and profit after tax. Standalone income also showed significant growth compared to the preceding quarter. Aayush Wellness is launching new products to expand its presence in preventive healthcare and nutraceutical markets.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/pvcVQ2H
via IFTTT

Govt plans instant ban on manufacturing of drugs failing key quality tests

Pharma companies could have their drug licenses suspended immediately if quality tests indicate failure. The health ministry's proposed changes aim to protect public health by enforcing swift action on substandard medications. Regulators would take action upon receiving a government analyst's report declaring a drug not of standard quality. Manufacturers would need to perform a root cause analysis and implement corrective actions to lift the suspension.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/JWATw2S
via IFTTT

Inside Park Hospitals' regional playbook: Why North India depth matters more than national reach

Park Hospitals is on an ambitious expansion journey, targeting around 6,600 beds by December 2028 across North India. Their strategy focuses on building hospitals in close proximity for better operational efficiency. The new Prayagraj initiative underscores a successful public-private partnership and illustrates their commitment to enhance healthcare capacity, ultimately improving patient care and resource management in the region.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/XBV846w
via IFTTT

HRV Pharma buys Germany's Phatebo

The acquisition marks virtual pharmaceutical company HRV's entry beyond active pharmaceutical ingredients (APIs) into finished formulations, giving it its first finished formulations business alongside a licenced operating entity in Germany.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/QKt3eqY
via IFTTT

NPPA updates list of reduced MRP of 1,085 anti-cancer drugs

The National Pharmaceutical Pricing Authority updated the maximum retail price for 1,085 anti-cancer medicines. This revision follows a previous decrease of prices for 543 anti-cancer drugs announced on October 28. The updated list contains prices based on information submitted by pharmaceutical companies up to November 3. The NPPA will continuously update this list as more manufacturers submit revised prices.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/Nwgr3iq
via IFTTT

Alkem Laboratories appoints Amrut Naik as CEO

Alkem Laboratories announced the appointment of Amrut Naik as its new Chief Executive Officer. His appointment is effective from November 11, following board approval and nomination committee recommendations. Naik has more than 26 years of experience in various areas, including pharmaceuticals and biologics. He holds both a bachelor's and master's degree in pharmaceutical science alongside a PhD in pharmacology.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/Qhj5Lzp
via IFTTT

High Court restrains NPPA from action against AstraZeneca

The Delhi High Court has issued a temporary restraining order against the NPPA's actions toward AstraZeneca Pharma. This order remains in effect until the next hearing date, January 11. AstraZeneca has argued that its product may not fall under controlled drug prices. The NPPA has accused AstraZeneca of overcharging for the inhaler from May 2016 to November 2025. AstraZeneca denies these allegations and claims compliance with the price regulations.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/91SKhc4
via IFTTT

Wockhardt expands novel antibiotic Miqnaf's access; Q2 revenue rises 24%

Wockhardt has expanded its marketing access for Miqnaf in India following the removal of a supply condition. The company's biotechnology sector recorded significant revenue growth, indicating strong demand for its products. Zaynich received US FDA approval for complicated urinary tract infections, serving as a milestone for Indian pharmaceuticals.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/hyKNisU
via IFTTT

Experts say health technology, preventive healthcare at inflection point, India ready to leverage

With a focus on preventive healthcare and wellness, India is on the verge of harnessing new technological innovations. Sangita Reddy from Apollo Hospitals stresses the significance of wearable devices in spotting health issues early on. In collaboration with Apollo Hospitals, Garmin Health is targeting rural health efforts and highlighting the event's health technology strides.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/1BwDgi8
via IFTTT

India’s medicine sales grow in double digits for four straight quarters, led by chronic care drugs

Over the past four quarters, India's medicine sales have increased significantly due to rising demand in chronic care segments. The growth rate reached 12% year-on-year in the September quarter, showing a positive trend in the industry. Larger pharmaceutical companies have benefited from the shutdown of many non-compliant smaller units. Budgets were also boosted by a reduction in GST on medicines.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/ztCd01h
via IFTTT